Key terms
About INDP
Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest INDP news
Mar 25
8:52am ET
Indaptus Therapeutics previews presentation of mechanism of action data
Mar 14
1:55pm ET
Buy Rating Affirmed for Indaptus Therapeutics Amid Positive Clinical and Financial Outlook
Mar 13
7:32am ET
Indaptus Therapeutics expects cash to support activities through 3Q24
Mar 13
7:32am ET
Indaptus Therapeutics reports 2023 EPS ($1.83) vs. ($1.73) last year
Mar 06
2:15pm ET
Buy Rating Affirmed on Indaptus Therapeutics as Decoy20 Advances in Phase 1 with Promising Developments
Mar 04
7:33am ET
Indaptus announces results from second cohort in Phase 1 INDP-D101 trial
Feb 08
8:09am ET
Indaptus Therapeutics launches new social media initiative to provide education
Jan 04
8:32am ET
Indaptus Therapeutics to receive European patent for platform technology
No recent news articles are available for INDP
No recent press releases are available for INDP
INDP Financials
Key terms
Ad Feedback
INDP Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
INDP Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range